When the Denominator Disappears: FDA's Next Evolution Should Be Causal Inference
The FDA advisory committee's vote against Capricor Therapeutics' cell therapy for Duchenne muscular dystrophy highlights a broader challenge: precision medicine shrinks patient populations, making tra…